Insomnia Market

Insomnia Market (Treatment Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Insomnia Market Outlook 2031

  • The global industry was valued at US$ 3.8 Bn in 2022
  • It is estimated to grow at a CAGR of 6.0% from 2023 to 2031 and reach US$ 6.4 Bn by the end of 2031

Analyst Viewpoint

Rise in prevalence of mental disorders is propelling the insomnia market size. Increase in work related stress is leading to surge in cases of sleep disorders across age groups globally. Smart wearable medical devices integrated with smartphone applications are gaining popularity for sleep management.

Growth in geriatric population is driving the insomnia market expansion. Prominent players operating in the global insomnia industry are investing in the R&D of novel drug formulations to combat sleep irregularity and anxiety. Manufacturers are also working on innovating drugs that are effective in smaller dosages to reduce the risk of addiction.

Insomnia Market

Market Introduction

Insomnia is the most common sleep disorder, affecting around 35% of the population worldwide. A minimum of seven hours of sleep is required for adults to lead a healthy lifestyle. However, a third of the global population gets less than required, which is affecting their long-term physical and mental health.

Insomnia therapeutics are commonly available as low dose sedating anti-depressants and nonbenzodiazepines. The global insomnia industry is heavily fragmented with several high barrier points to entry such as product efficacy, innovation, and cost. In recent times, the rise in stress levels is leading to high incidences of mental disorders, which is fueling the insomnia market revenue.

Rise in Prevalence of Mental Disorders Fueling Insomnia Market Development

The current socio-economic climate coupled with work-life stress is boosting the prevalence of mental disorders across demographics. Anxiety, depression, and other mental illnesses are linked to several sleep disorders such as insomnia and obstructive sleep apnea. Symptoms of insomnia, including wakefulness and anxiety, may seem benign but can lead to flawed judgment, accidents, and even death.

According to American Academy of Sleep Medicine, mental health issues and substance abuse are prominent causes of sleep disorders in 3% of the global adult population. Over one-fifth of the population suffers from stress-related loss of sleep each year. In the U.S., US$ 94.9 Bn is spent each year on sleep disorder care and therapeutics.

Surge in Geriatric Population Driving Insomnia Market Demand

Chronic and acute insomnia is evident in the majority of the elderly population worldwide. Older people usually suffer from an inability to maintain sleep. Management of sleep disorders in such patients is complex and requires careful evaluation of underlying medical conditions and ongoing treatments. Hence, rise in geriatric population is fueling the insomnia market progress.

In male patients, lack of sleep is co-related with morbidity, morality, and enhanced risk of nursing home placements. A range of therapeutic care offerings exist for the elderly. R&D of new drugs is expected to spur the insomnia market growth in the near future. In December 2022, Zydus Lifesciences received final approval from the U.S. Food and Drug Administration to market Triazolam tablets 0.125 mg and 0.25 mg. for the treatment of insomnia on a short-term basis.

Regional Outlook

According to the latest insomnia market analysis, North America held largest share in 2022. Surge in cases of sleeping disorders and increase in healthcare expenditure are augmenting the market dynamics of the region. According to the American Sleep Association, about 70 million people in the U.S. suffer from sleeping disorders. Men constitute a significant proportion of this group.

According to the latest insomnia industry forecast, the industry in Asia Pacific is projected to grow at a steady pace from 2023 to 2031. High-stress work culture is propelling the insomnia market statistics in the region.

Analysis of Key Players

According to the recent insomnia market trends, prominent manufacturers are investing heavily in the development of next-gen insomnia drugs to combat nighttime wakefulness. They are developing smart and wearable sleep-inducing devices. These devices are integrated with mobile applications and designed specifically to enable patients to sleep faster for a relatively healthy amount of time.

Paratek Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi S.A, Merck & Co., Inc., and Viatris Inc. are key companies operating in this market.

These companies have been profiled in the insomnia market report based on various parameters such as company overview, product portfolio, business strategies, financial overview, and business segments.

Key Developments

  • In November 2023, Neurovalens, a Belfast-based healthcare start-up, received the U.S. Food and Drug Administration approval for Modius Sleep Band, a non-invasive chronic insomnia treatment device
  • In April 2023, the South Korean Ministry of Food and Drug Safety approved WELT-I, a digital therapeutics app for the treatment of insomnia

Insomnia Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 3.8 Bn
Market Forecast Value in 2031 US$ 6.4 Bn
Growth Rate (CAGR) 6.0%
Forecast Period 2023 to 2031
Historical Data Available for 2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Market Segmentation
  • Treatment Type
    • Benzodiazepines
    • Nonbenzodiazepines
    • Antidepressants
    • Orexin Antagonist
    • Melatonin Antagonist
    • Devices
    • Others
  • Sales Channel
    • Hospital Pharmacies
    • Retail Pharmacies and Drug Stores
    • Online Pharmacies
Companies Profiled
  • Paratek Pharmaceuticals, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • Vanda Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sanofi S.A
  • Merck & Co., Inc.
  • Viatris Inc.
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the global insomnia market in 2022?

It was valued at US$ 3.8 Bn in 2022

How is the insomnia business expected to grow by 2031?

It is projected to grow at a CAGR of 6.0% from 2023 to 2031

What are the key factors driving the demand for insomnia?

Rise in prevalence of mental disorders and surge in geriatric population

Which insomnia treatment type segment held the largest share in 2022?

The benzodiazepines segment held the largest share in 2022

Which was the major region in the global insomnia industry in 2022?

North America dominated the global landscape in 2022

Who are the key insomnia manufacturers?

Paratek Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi S.A, Merck & Co., Inc., and Viatris Inc.

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Insomnia Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Insomnia Market Analysis and Forecasts, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Disease Prevalence & Incidence Rate Globally with Key Countries

        5.3. COVID-19 Pandemic Impact on Industry

    6. Insomnia Market Analysis and Forecast, by Treatment Type

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Treatment Type, 2017–2031

            6.3.1. Benzodiazepines

            6.3.2. Nonbenzodiazepines

            6.3.3. Antidepressants

            6.3.4. Orexin Antagonist

            6.3.5. Melatonin Antagonist

            6.3.6. Devices

            6.3.7. Others

        6.4. Market Attractiveness, by Treatment Type

    7. Global Insomnia Market Analysis and Forecast, by Sales Channel

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Sales Channel, 2017–2031

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies and Drug Stores

            7.3.3. Online Pharmacies

        7.4. Market Attractiveness, by Sales Channel

    8. Global Insomnia Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2017–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Insomnia Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Treatment Type, 2017–2031

            9.2.1. Benzodiazepines

            9.2.2. Nonbenzodiazepines

            9.2.3. Antidepressants

            9.2.4. Orexin Antagonist

            9.2.5. Melatonin Antagonist

            9.2.6. Devices

            9.2.7. Others

        9.3. Market Value Forecast, by Sales Channel, 2017–2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies and Drug Stores

            9.3.3. Online Pharmacies

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Treatment Type

            9.5.2. By Sales Channel

            9.5.3. By Country

    10. Europe Insomnia Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment Type, 2017–2031

            10.2.1. Benzodiazepines

            10.2.2. Nonbenzodiazepines

            10.2.3. Antidepressants

            10.2.4. Orexin Antagonist

            10.2.5. Melatonin Antagonist

            10.2.6. Devices

            10.2.7. Others

        10.3. Market Value Forecast, by Sales Channel, 2017–2031

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies and Drug Stores

            10.3.3. Online Pharmacies

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Treatment Type

            10.5.2. By Sales Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Insomnia Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment Type, 2017–2031

            11.2.1. Benzodiazepines

            11.2.2. Nonbenzodiazepines

            11.2.3. Antidepressants

            11.2.4. Orexin Antagonist

            11.2.5. Melatonin Antagonist

            11.2.6. Devices

            11.2.7. Others

        11.3. Market Value Forecast, by Sales Channel, 2017–2031

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies and Drug Stores

            11.3.3. Online Pharmacies

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Treatment Type

            11.5.2. By Sales Channel

            11.5.3. By Country/Sub-region

    12. Latin America Insomnia Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment Type, 2017–2031

            12.2.1. Benzodiazepines

            12.2.2. Nonbenzodiazepines

            12.2.3. Antidepressants

            12.2.4. Orexin Antagonist

            12.2.5. Melatonin Antagonist

            12.2.6. Devices

            12.2.7. Others

        12.3. Market Value Forecast, by Sales Channel, 2017–2031

            12.3.1. Hospital Pharmacies

            12.3.2. Retail Pharmacies and Drug Stores

            12.3.3. Online Pharmacies

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Treatment Type

            12.5.2. By Sales Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Insomnia Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment Type, 2017–2031

            13.2.1. Benzodiazepines

            13.2.2. Nonbenzodiazepines

            13.2.3. Antidepressants

            13.2.4. Orexin Antagonist

            13.2.5. Melatonin Antagonist

            13.2.6. Devices

            13.2.7. Others

        13.3. Market Value Forecast, by Sales Channel, 2017–2031

            13.3.1. Hospital Pharmacies

            13.3.2. Retail Pharmacies and Drug Stores

            13.3.3. Online Pharmacies

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Treatment Type

            13.5.2. By Sales Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Paratek Pharmaceuticals, Inc.

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Treatment Type Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Sumitomo Dainippon Pharma Co., Ltd.

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Treatment Type Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. Teva Pharmaceutical Industries Limited

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Treatment Type Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. Vanda Pharmaceuticals Inc.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Treatment Type Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. Takeda Pharmaceutical Company Limited

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Treatment Type Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. Pfizer Inc.

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Treatment Type Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            14.3.7. Sanofi S.A

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Treatment Type Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. Merck & Co., Inc.

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Treatment Type Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

            14.3.9. Viatris Inc.

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Treatment Type Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. SWOT Analysis

                14.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 02: Global Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031

    Table 03: Global Insomnia Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 05: North America Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031

    Table 06: North America Insomnia Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: Europe Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 08: Europe Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031

    Table 09: Europe Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 11: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031

    Table 12: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Latin America Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 14: Latin America Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031

    Table 15: Latin America Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 17: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031

    Table 18: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Insomnia Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Insomnia Market Value Share Analysis, by Treatment Type 2022 and 2031

    Figure 03: Global Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031

    Figure 04: Global Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031

    Figure 05: Global Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031

    Figure 06: Global Insomnia Market Value Share Analysis, by Region, 2022 and 2031

    Figure 07: Global Insomnia Market Attractiveness Analysis, by Region, 2017–2031

    Figure 08: North America Insomnia Market Value (US$ Mn) Forecast, 2017–2031

    Figure 09: North America Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 10: North America Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031

    Figure 11: North America Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031

    Figure 12: North America Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031

    Figure 13: North America Insomnia Market Value Share Analysis, by Country, 2022 and 2031

    Figure 14: North America Insomnia Market Attractiveness Analysis, by Country, 2017–2031

    Figure 15: Europe Insomnia Market Value (US$ Mn) Forecast, 2017–2031

    Figure 16: Europe Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 17: Europe Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031

    Figure 18: Europe Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031

    Figure 19: Europe Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031

    Figure 20: Europe Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 21: Europe Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 22: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, 2017–2031

    Figure 23: Asia Pacific Insomnia Market Value Share Analysis, by Treatment Type 2022 and 2031

    Figure 24: Asia Pacific Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031

    Figure 25: Asia Pacific Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031

    Figure 26: Asia Pacific Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031

    Figure 27: Asia Pacific Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 28: Asia Pacific Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 29: Latin America Insomnia Market Value (US$ Mn) Forecast, 2017–2031

    Figure 30: Latin America Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 31: Latin America Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031

    Figure 32: Latin America Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031

    Figure 33: Latin America Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031

    Figure 34: Latin America Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 35: Latin America Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 36: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, 2017–2031

    Figure 37: Middle East & Africa Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 38: Middle East & Africa Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031

    Figure 39: Middle East & Africa Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031

    Figure 40: Middle East & Africa Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031

    Figure 41: Middle East & Africa Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 42: Middle East & Africa Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 43: Global Insomnia Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved